In a groundbreaking move, NextCure, Inc. has recently published a preclinical study in the esteemed journal Science Advances, shedding light on the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) as a T cell inhibitor. This discovery holds immense promise for the development of novel immunomedicines to effectively combat cancer and other immune-related diseases. In this article, we will outline the key facts from the study and assess the potential impact on NextCure, Inc.
Facts:NextCure, Inc. has published a manuscript
Comments